» Articles » PMID: 35677335

Development of Two Diagnostic Prediction Models for Leptomeningeal Metastasis in Patients With Solid Tumors

Overview
Journal Front Neurol
Specialty Neurology
Date 2022 Jun 9
PMID 35677335
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: For accurate diagnosis of leptomeningeal metastasis (LM) and to avoid unnecessary examinations or lumber puncture (LP), we develop two diagnostic prediction models for patients with solid tumors.

Study Design Setting And Participants: This is a retrospective cohort study launched at the Second Affiliated Hospital of Dalian Medical University. In total, 206 patients who had been admitted between January 2005 and December 2021 with a solid tumor and clinical suspicion of LM were enrolled to develop model A. In total, 152 patients of them who underwent LPs for cytology and biochemistry were enrolled to develop model B.

Model Development: Diagnostic factors included skull metastasis, active brain metastasis, progressed extracranial disease, number of extracranial organs involved, number of symptoms, cerebrospinal fluid (CSF) protein, and CSF glucose. The outcome predictor was defined as the clinical diagnosis of LM. Logistic least absolute shrinkage and selection operator (LASSO) regression was used to identify relevant variables and fit the prediction model. A calibration curve and the concordance index (c-index) were used to evaluate calibration and discrimination ability. The -fold cross-validation method was used to internally validate the models. The decision curve analysis (DCA) and the interventions avoided analysis (IAA) were used to evaluate the clinical application.

Results: The area under the curve (AUC) values of models A and B were 0.812 (95% CI: 0.751-0.874) and 0.901 (95% CI: 0.852-0.949). Respectively, compared to the first magnetic resonance imaging (MRI) and first LP, models A and B showed a higher AUC (model A vs. first MRI: 0.812 vs. 0.743, = 0.087; model B vs. first LP: 0.901 vs. 0.800, = 0.010). The validated c-indexes were 0.810 (95% CI: 0.670-0.952) and 0.899 (95% CI: 0.823-0.977). The calibration curves show a good calibrated ability. The evaluation of clinical application revealed a net clinical benefit and a reduction of unnecessary interventions using the models.

Conclusions: The models can help improve diagnostic accuracy when used alone or in combination with conventional work-up. They also exhibit a net clinical benefit in medical decisions and in avoiding unnecessary interventions for patients with LM. Studies focused on external validation of our models are necessary in the future.

Citing Articles

Leptomeningeal metastatic disease: new frontiers and future directions.

Ozair A, Wilding H, Bhanja D, Mikolajewicz N, Glantz M, Grossman S Nat Rev Clin Oncol. 2024; 22(2):134-154.

PMID: 39653782 DOI: 10.1038/s41571-024-00970-3.


A non-enhancing, T2 fluid-attenuated inversion recovery hyperintense, diffusion-restricting brainstem lesion in an EGFR tyrosine kinase inhibitor-treated non-small-cell lung cancer patient.

Yuen C, Bao S, Kong X Biomark Med. 2024; 18(9):431-439.

PMID: 39007837 PMC: 11285344. DOI: 10.1080/17520363.2024.2342231.


Development and validation of a nomogram to predict leptomeningeal metastases in lung adenocarcinoma: Cervical lymph node metastasis is an important association factor.

Hua X, Feng W, Ye M, Lai M, Yu X, Sun M Cancer Med. 2024; 13(9):e7206.

PMID: 38686619 PMC: 11058696. DOI: 10.1002/cam4.7206.

References
1.
Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

2.
Collins G, Reitsma J, Altman D, Moons K . Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med. 2015; 162(1):55-63. DOI: 10.7326/M14-0697. View

3.
Zagouri F, Zoumpourlis P, Le Rhun E, Bartsch R, Zografos E, Apostolidou K . Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: A metanalysis with meta-regression. Cancer Treat Rev. 2020; 88:102046. DOI: 10.1016/j.ctrv.2020.102046. View

4.
Ferguson S, Fomchenko E, Guerrieri R, Glitza Oliva I . Challenges and Advances in Diagnosis and Treatment of Leptomeningeal Disease (LMD). Front Oncol. 2022; 11:800053. PMC: 8789647. DOI: 10.3389/fonc.2021.800053. View

5.
Park J, Kim Y, Lee J, Lee K, Kim J, Bang S . Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era. Lung Cancer. 2011; 76(3):387-92. DOI: 10.1016/j.lungcan.2011.11.022. View